Wang Li-Ju, Naudé Nicole, Chang Yu-Chung, Crivaro Anne, Kamoun Malek, Wang Ping, Li Lei
School of Mechanical and Materials Engineering, Washington State University, Pullman, Washington.
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
J Biophotonics. 2018 Aug;11(8):e201700382. doi: 10.1002/jbio.201700382. Epub 2018 Apr 29.
With the rapid development and proliferation of mobile devices with powerful computing power and the ability of integrating sensors into mobile devices, the potential impact of mobile health (mHealth) diagnostics on the public health is drawing researchers' attention. We developed a Smartphone Octo-channel Spectrometer (SOS) as a mHealth diagnostic tool. The SOS has nanoscale wavelength resolution, is self-illuminated from the smartphone itself, and is ultra-low cost (less than $20). A user interface controls the optical sensing parameters and precise alignment. After calibrating and testing the SOS by quantifying protein concentrations, we clinically validated the SOS by comparing the diagnostic performance of our device with that of a clinical spectrophotometer. About 180 serum samples from de-identified patients with 4 types of autoantibodies were blindly read the ELISA results. The accuracy of the SOS achieved 100% across the clinical reportable range compared with the FDA-approved instrument. Furthermore, the self-illuminated SOS only requires about half of the light intensity of the FDA-approved instrument to achieve clinical-level sensitivity. The low-energy-consumption and low-cost SOS enables point-of-care spectrophotometric sensing in low-resource areas, and can be integrated into point-of-care diagnostic systems for rapid multiplex readout and analysis at patient bedside or at home.
随着具备强大计算能力且能将传感器集成其中的移动设备迅速发展与普及,移动健康(mHealth)诊断技术对公共卫生的潜在影响正吸引着研究人员的关注。我们开发了一款智能手机八通道光谱仪(SOS)作为一种移动健康诊断工具。该SOS具有纳米级波长分辨率,由智能手机自身自发光,且成本超低(不到20美元)。一个用户界面可控制光学传感参数及精确对准。在通过量化蛋白质浓度对SOS进行校准和测试后,我们通过将我们设备的诊断性能与临床分光光度计的诊断性能进行比较,对SOS进行了临床验证。对来自身份不明的患有4种自身抗体的患者的约180份血清样本进行了ELISA结果的盲读。与FDA批准的仪器相比,SOS在整个临床可报告范围内的准确率达到了100%。此外,自发光的SOS仅需FDA批准仪器约一半的光强度就能达到临床级灵敏度。低能耗且低成本的SOS能够在资源匮乏地区实现即时护理分光光度传感,并且可以集成到即时护理诊断系统中,以便在患者床边或家中进行快速多重读出和分析。